Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Has Consensus Price Target of $8.20

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been assigned a consensus recommendation of “Reduce” from the twelve research firms that are covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $8.20.

A number of analysts have recently commented on FULC shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Friday, July 17th. Citigroup downgraded shares of Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a research report on Tuesday, June 2nd. Cantor Fitzgerald lowered shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Leerink Partners cut shares of Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 price target on the stock. in a research report on Tuesday, June 2nd. Finally, HC Wainwright downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research note on Tuesday, June 2nd.

Institutional Trading of Fulcrum Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Summit Securities Group LLC bought a new position in Fulcrum Therapeutics in the first quarter valued at approximately $53,000. The Manufacturers Life Insurance Company bought a new stake in shares of Fulcrum Therapeutics during the 2nd quarter worth approximately $61,000. ProShare Advisors LLC acquired a new stake in shares of Fulcrum Therapeutics in the 4th quarter valued at approximately $116,000. Westshore Wealth LLC bought a new position in shares of Fulcrum Therapeutics in the first quarter valued at $130,000. Finally, Marquette Asset Management LLC bought a new position in shares of Fulcrum Therapeutics in the second quarter valued at $141,000. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Performance

NASDAQ:FULC opened at $3.72 on Friday. The company has a market cap of $283.84 million, a PE ratio of -3.07 and a beta of 2.59. Fulcrum Therapeutics has a 52-week low of $2.83 and a 52-week high of $15.74. The stock has a 50-day simple moving average of $3.79 and a 200 day simple moving average of $5.13.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Thursday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.10). On average, research analysts predict that Fulcrum Therapeutics will post -0.6 earnings per share for the current fiscal year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for genetically driven diseases that affect skeletal muscle and other tissues. The company uses its FulcrumSeek drug-discovery platform to identify molecular targets and potential therapies for conditions in which the underlying biology is well characterized but treatment options remain limited.

Fulcrum’s lead product candidate is losmapimod, an investigational oral therapy being developed for facioscapulohumeral muscular dystrophy (FSHD), a rare inherited muscle-wasting disorder.